Skip to content
Nootropic
Geek — Home
Home/News/Adderall Misuse and Emergency Visits: The 2016 Report
News

Adderall Misuse and Emergency Visits: The 2016 Report

Read the article ↓

Nootropic Geek is an affiliate publisher. Some links may earn us a commission. Disclosure · Editorial standards

Adderall Misuse and Emergency Visits: The 2016 Report

news logo

Historical news: this article concerns research reported in February 2016 using United States data from 2006–2011. Its figures do not describe current emergency visits or establish the prevalence of nonmedical stimulant use on today’s campuses.

The finding behind the headline

Johns Hopkins reported that, among young adults during the study period, non-prescribed Adderall use increased by 67% and associated emergency-department visits increased by 156%, while prescriptions did not show a corresponding increase. Researchers combined prescribing, population-survey and emergency-visit data sources.

These are changes relative to earlier measured levels, not percentages of all students or all users. They cannot be converted into a claim that most students use stimulants or that a particular user will experience an emergency.

Nonmedical use is not off-label prescribing

The original article blurred these terms. Off-label prescribing means a clinician prescribes an approved medicine outside an approved indication or other label condition. Nonmedical use includes taking someone else’s prescription or otherwise misusing medicine. These are different situations.

The report identified friends and relatives as an important source of diverted medication. That observation supports attention to sharing and storage, not stigmatizing people appropriately treated for ADHD.

What the study did not establish

Separate datasets reveal patterns but do not follow every person from access to an emergency visit. They also do not establish that increasing use caused every reported event. The original article’s broad estimate that 20–40% of university students had used smart drugs lacked a sufficiently defined population and is not retained as a reliable prevalence estimate.

Modafinil appeared in contemporary reporting too, but calling it a universally safe smart drug exceeded the evidence. Selected short-term studies cannot establish absence of long-term harms or suitability for every healthy user.

Why the distinction still matters

Prescription stimulants have legitimate medical uses and serious misuse risks. FDA’s later safety communication emphasizes addiction, overdose and sharing. That guidance supplies safety context, not an update to the historical statistics.

The enduring lesson is to distinguish treatment from diversion and match statistics to their dates and source population. For learning and revision, see the student guide. This page remains historical reporting, not a rolling claim that emergency visits are currently increasing.

Sources and further reading

Continue exploring
More from Nootropic Geek

Related reading.